Trial reportBiomolecules2019
Elevated Plasma microRNA-206 Levels Predict Cognitive Decline and Progression to Dementia from Mild Cognitive Impairment.
Trial report in Biomolecules, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 3 syntheses or guidelines pooled it, 66 citations in OpenAlex.
- Non-coding RNAs and Mitochondrial Dysfunction in Alzheimer's Disease: A Systematic Review.Molecular neurobiology · 2026Pooled it
- Prediction of differentially expressed microRNAs in blood as potential biomarkers for Alzheimer's disease by meta-analysis and adaptive boosting ensemble learning.Alzheimer's research & therapy · 2021Pooled it
- Systematic Review: microRNAs as Potential Biomarkers in Mild Cognitive Impairment Diagnosis.Frontiers in aging neuroscience · 2021Pooled it
- Peripheral and Central miRNA Signatures in Alzheimer's Disease: Tissue-Specific Variability, Sex-Associated Differences, and Implications for Blood-Based Biomarkers.International journal of molecular sciences · 2026Review
- MicroRNA and Alzheimer's disease: Diagnostic biomarkers and potential therapeutic targets.Neural regeneration research · 2026Article
- Fecal miRNome and Proteome Profiling Uncovers Stage-Specific Biomarkers of Alzheimer's Disease in 3×Tg-AD Mice.Cellular and molecular neurobiology · 2026Article
- Label-Free Electrochemical Biosensors: An Updated Perspective Focused on Genosensing, Multiplexing, and Commercial Potential.Biosensors · 2026Review
- Dual-responsive zwitterionic hydrogel microneedle patch for the on-site detection of two alzheimer's disease - related miRNAs.Journal of nanobiotechnology · 2026Article
- Circulating Biomarkers for the Early Diagnosis of Alzheimer's Disease.International journal of molecular sciences · 2025Review
- The miR-133b and miR-206 serum levels as a candidate biomarker in Alzheimer's patients with dyslipidemia.IBRO neuroscience reports · 2025Article
- Microfluidic Systems: Recent Advances in Chronic Disease Diagnosis and Their Therapeutic Management.Indian journal of microbiology · 2025Article
- The challenge of chemotherapy-related cognitive impairment: assessing and managing cognitive decline after cancer treatment.Ecancermedicalscience · 2025Review
- New Research on Biomarkers in Alzheimer's Continuum.Reviews on recent clinical trials · 2025Review
- Biofluid biomarkers for Alzheimer's disease: past, present, and future.Medical review (2021) · 2024Review
- Current trends and hotspots of depressive disorders with colorectal cancer: A bibliometric and visual study.World journal of gastrointestinal oncology · 2024Article
- The Neuromuscular Disorder Mediated by Extracellular Vesicles in Amyotrophic Lateral Sclerosis.Current issues in molecular biology · 2024Review
- Epigenetics in Alzheimer's Disease: A Critical Overview.International journal of molecular sciences · 2024Review
- Role of microRNAs in cognitive decline related to COVID‑19 (Review).Experimental and therapeutic medicine · 2024Review
- Biological and Physical Performance Markers for Early Detection of Cognitive Impairment in Older Adults.Journal of clinical medicine · 2024Review
- Unveiling the Complex Role of Exosomes in Alzheimer's Disease.Journal of inflammation research · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 5 institutions in 2 countries.
Funding
Abstract
The need for practical biomarkers for early diagnosis of Alzheimer's disease (AD) remains largely unmet. Here we investigated the use of blood-based microRNAs as prognostic biomarkers for AD and their application in a novel electrochemical microfluidic device for microRNA detection. MicroRNA transcriptome was profiled in plasma from patients with mild cognitive impairment (MCI) and AD. MicroRNAs Let-7b and microRNA-206 were validated at elevated levels in MCI and AD, respectively. MicroRNA-206 displayed a strong correlation with cognitive decline and memory deficits. Longitudinal follow-ups over five years identified microRNA-206 increases preceding the onset of dementia. MicroRNA-206 was increased in unprocessed plasma of AD and MCI subjects, detected by our microfluidic device. While increased Let-7b levels in plasma may be used to identify patients with MCI, changes in plasma levels of microRNA-206 may be used to predict cognitive decline and progression towards dementia at an MCI stage. MicroRNA quantification via a microfluidic device could provide a practical cost-effective tool for the stratification of patients with MCI according to risk of developing AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.